92,488 results match your criteria Lung Cancer Non-Small Cell

Acquired Resistance to KRAS Inhibition in Cancer.

N Engl J Med 2021 Jun;384(25):2382-2393

From Dana-Farber Cancer Institute (M.M.A., S.L., J.D., J.O.J., K.E.L., H.F., K.M.H., B.M.W., P.A.J., A.J.A.), Massachusetts General Hospital (R.S.H., Y.P.H.), and Brigham and Women's Hospital (L.M.S., A.J.A.), Boston, and Broad Institute of MIT and Harvard (S.L., X.Y., N.S.P., D.E.R., K.M.H., A.J.A.) and Foundation Medicine (J.L., A.B.S.), Cambridge - all in Massachusetts; Henry Ford Cancer Institute, Detroit (I.I.R.); Memorial Sloan Kettering Cancer Center, New York (K.C.A., G.J.R., P.L.); Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (V.W.Z., S.S.Z., S.-H.I.O.), Boundless Bio, La Jolla (J.W., J.C.), and Mirati Therapeutics, San Diego (L.D.E., L.W., J.D.L., P.O., J.G.C.) - all in California; Sarah Cannon Research Institute, Tennessee Oncology/OneOncology, Nashville (M.L.J.); the University of Colorado, Aurora (T.P.); and Resolution Bioscience, Kirkland, WA (L.P.L., K.G., M.L.).

Background: Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at codon 12 (KRAS). The mechanisms of acquired resistance to these therapies are currently unknown.

Methods: Among patients with -mutant cancers treated with adagrasib monotherapy, we performed genomic and histologic analyses that compared pretreatment samples with those obtained after the development of resistance. Read More

View Article and Full-Text PDF

Postoperative transient elevation of serum cancer antigen 125 in non-small cell lung cancer patients.

Yiwang Ye

Rev Assoc Med Bras (1992) 2021 Jan;67(1):39-44

Peking University Shenzhen Hospital - Shenzhen, China.

Objective: The aim of this retrospective study was to investigate the correlation of transiently elevated postoperative serum cancer antigen 125 levels and prognosis in patients with non-small cell lung cancer.

Methods: A total of 181 non-small cell lung cancer patients with normal levels of preoperative serum cancer antigen 125 were statistically summarized in this study.

Results: Out of the analyzed patients, 22 (12. Read More

View Article and Full-Text PDF
January 2021

["Treatment of lung cancer with immune checkpoints inhibitors"].

Rev Prat 2021 Apr;71(4):385-390

Département de cancérologie médicale, centre Léon-Bérard, Lyon, France.

"Treatment of lung cancer with immune checkpoints inhibitors .Immunotherapy has considerably changed the treatment of lung cancer. Anti-PD-1 or anti-PD-L1, either as monotherapy or in combination with chemotherapy, are now the cornerstone of the treatment of metastatic non-small cell lung cancer and enable some patients to achieve prolonged survival, sometimes without evidence of residual disease. Read More

View Article and Full-Text PDF

Survival Outcomes of Lobectomy Versus Segmentectomy in Clinical Stage I Non-Small Cell Lung Cancer: A Meta-Analysis.

Adv Ther 2021 Jun 23. Epub 2021 Jun 23.

Department of Thoracic Surgery, Funing People's Hospital, No. 111 Fcheng Street Road, Funing County, Yancheng City, 224400, Jiangsu Province, China.

Introduction: The gold standard surgical therapy for patients with clinical stage I non-small cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection. Meanwhile, segmentectomy has emerged as an alternative choice with the advantage of fewer postoperative complications. The acceptance of this procedure remains controversial, and conflicting results exist in the retrospective trials. Read More

View Article and Full-Text PDF

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.

Medicine (Baltimore) 2021 Jun;100(25):e26450

Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou.

Rationale: The guidelines recommended gefitinib as a first-line targeted treatment for stage IV non-small-cell lung cancer (NSCLC) patients with EGFR mutations. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment for patients without T790m mutation. The case is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. Read More

View Article and Full-Text PDF

1,3-Benzodioxole Modified Noscapine Analogues: Synthesis, Antiproliferative Activity and Tubulin Bound Structure.

ChemMedChem 2021 Jun 22. Epub 2021 Jun 22.

Monash University, Dept. of Medicinal Chemistry, 381 Royal Parade, 3052, Parkville, AUSTRALIA.

Since the revelation of noscapine's weak anti-mitotic activity, extensive research has been conducted over the past two decades, with the goal of discovering noscapine derivatives with improved potency. To date, noscapine has been explored at the 1, 7, 6', and 9'-positions, though the 1,3-benzodioxole motif in the noscapine scaffold that remains unexplored. The present investigation describes the design, synthesis and pharmacological evaluation of noscapine analogues consisting of modifications to the 1,3-benzodioxole moiety. Read More

View Article and Full-Text PDF

A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib.

Thorac Cancer 2021 Jun 23. Epub 2021 Jun 23.

Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan.

Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangements are found in ~ 5% of patients with non-small cell lung cancer (NSCLC). Several tyrosine kinase inhibitors (TKIs) have been developed for treatment of so-called ALK-positive NSCLC. In cases of tumor progression during treatment with second-generation ALK-TKIs, such as alectinib, brigatinib, or ceritinib, National Comprehensive Cancer Network guidelines propose a switch to lorlatinib, a third-generation ALK-TKI, or to cytotoxic chemotherapy. Read More

View Article and Full-Text PDF

Prophylactic cranial irradiation confers favourable prognosis for patients with limited-stage small cell lung cancer in the era of MRI: A propensity score-matched analysis.

J Med Imaging Radiat Oncol 2021 Jun 22. Epub 2021 Jun 22.

Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

Introduction: Prophylactic cranial irradiation (PCI) is recommended for patients with limited-stage small cell lung cancer (LS-SCLC) who achieve good response after chemoradiotherapy. But PCI is neurotoxic. Magnetic resonance imaging (MRI) is the standard tool for evaluating brain metastasis (BM). Read More

View Article and Full-Text PDF

Transcutaneous Acupoint Electrical Stimulation on Chemotherapy-Induced Constipation for Non-Small Cell Lung Cancer Patients: A Randomized Controlled Trial.

Asia Pac J Oncol Nurs 2021 Jul-Aug;8(4):385-392. Epub 2021 Mar 12.

Department of Hospital Office, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

Objective: Chemotherapy-induced constipation (CIC) adversely affects the quality of life of non-small cell lung cancer (NSCLC) patients. This study aimed to investigate the clinical effects of transcutaneous acupoint electrical stimulation (TAES) on CIC.

Methods: Sixty NSCLC patients who received chemotherapy at Hunan Cancer Hospital, Changsha, China, were assigned to the TAES ( = 30) or control ( = 30) group using Research Randomizer. Read More

View Article and Full-Text PDF

A comprehensive comparison between young and older-age non-small cell lung cancer patients at a public referral centre in Delhi, India.

Ecancermedicalscience 2021 27;15:1223. Epub 2021 Apr 27.

Department of Pulmonary Medicine and Sleep Disorders, All India Institute of Medical Sciences, New Delhi 110608, India.

Purpose: Given the increasing number of non-small cell lung cancer (NSCLC) patients in India, a comparative analysis between patients under 40 years and those of older age at a major public referral centre would provide insight into the phenotypic patterns of this group.

Methods: NSCLC patients who were accessioned within the lung cancer clinic database of the Pulmonary Medicine Department at the all India institute of medical sciences - Delhi between 2008 and 2019 were reviewed. Patients 40 years or younger and 60 years or older were selected and categorised as young and older patients, respectively. Read More

View Article and Full-Text PDF

Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer.

Chin J Cancer Res 2021 Apr;33(2):203-215

Cancer Center, the First Hospital of Jilin University, Changchun 130021, China.

Immune checkpoint inhibitors (ICIs), a type of immunotherapy, have become one of the most important therapeutic options for first- and second-line treatment of advanced non-small cell lung cancer (NSCLC). Recent clinical studies have shown that immunotherapy can offer substantial survival benefits to patients with early-stage or resectable advanced NSCLC. However, considering the importance of timing when using ICIs and their associated adverse events (AEs), the advantages and disadvantages of using these agents need to be weighed carefully when deciding the use of a combined treatment. Read More

View Article and Full-Text PDF

SOX11 inhibitors are cytotoxic in mantle cell lymphoma.

Clin Cancer Res 2021 Jun 22. Epub 2021 Jun 22.

Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Purpose: Mantle Cell Lymphoma (MCL) is a fatal subtype of Non-Hodgkin's Lymphoma. SOX11 transcription factor is overexpressed in the majority of nodal MCL. We have previously reported that B-cell specific overexpression of SOX11 promotes MCL pathogenesis via critically increasing BCR signaling in vivo. Read More

View Article and Full-Text PDF

SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-naïve ALK-, ROS1-, or EGFR-altered non-small-cell lung cancer.

Mol Cancer Ther 2021 Jun 22. Epub 2021 Jun 22.

Department of Allergy and Respiratory Medicine, Okayama University Hospital.

After molecular-targeted therapy, some cancer cells may remain that are resistant to therapies targeting oncogene alterations, such as those in the genes encoding the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) as well as c-ros oncogene 1 (ROS1). The mechanisms underlying this type of resistance are unknown. Here we report the potential role of Src homology 2 domain-containing phosphatase 2 (SHP2) in the residual cells of ALK/ROS1/EGFR-altered non-small-cell lung cancer (NSCLC). Read More

View Article and Full-Text PDF

FDA Approves First KRAS Inhibitor: Sotorasib.


Cancer Discov 2021 Jun 22. Epub 2021 Jun 22.

The FDA has approved the first KRAS-targeted therapy, sotorasib, for patients with previously treated non-small cell lung cancer with KRASG12C mutations. In a phase II trial, the drug yielded a median progression-free survival of 6.8 months in patients whose disease had advanced despite treatment with standard therapies, namely platinum-based chemotherapy and PD-1-PD-L1 inhibitors. Read More

View Article and Full-Text PDF

Investigating efficacy of "microbiota modulation of the gut-lung Axis" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial.

BMC Cancer 2021 Jun 22;21(1):721. Epub 2021 Jun 22.

Institute of Energy Metabolism and Health, Tongji University School of Medicine, No. 301, Middle Yangchang Rd, Shanghai, 200072, China.

Background: Most NSCLCs metastasised out of the lungs at the time of diagnosis and cannot be surgically removed . Cytotoxic chemotherapy drugs have become the main treatment in recent decades, especially in patients with NSCLC without EGFR, ALK, and ROS gene mutations. The prognosis of lung cancer is poor, and the overall 5-year survival rate is only 9-13%. Read More

View Article and Full-Text PDF

[Comprehensive Treatment of An Advanced Lung Cancer Patient with 
EGFR Driver Gene Positive].

Zhongguo Fei Ai Za Zhi 2021 Jun;24(6):447-452

Department of Thoracic Surgery, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), 
Beijing 100080, China.

Lung cancer is the most common malignant tumor and the leading cause of cancer-related death worldwide. Most of the patients have distant metastasis when visiting the doctor, which seriously affects the survival time and quality of life of the patients. With the development of molecular targeted drugs, lung cancer treatment has been transformed from traditional chemotherapy to targeted therapy and precision medicine has been gradually applied in clinical practice, which can make lung cancer patients live longer and have a better quality of life. Read More

View Article and Full-Text PDF

Molecular follow-up of first-line treatment by osimertinib in lung cancer: Importance of using appropriate tools for detecting EGFR resistance mutation C797S.

Cancer Genet 2021 Jun 10;256-257:158-161. Epub 2021 Jun 10.

Laboratory of Solid Tumor Genetics, University Hospital of Nice-Côte d'Azur University, Nice, France; Laboratory of Solid Tumor Genetics, Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284/INSERM U1081, Nice, France. Electronic address:

The C797S mutation encoded by EGFR exon 20 is classically observed as a tertiary event in EGFR-mutant non-small-cell lung carcinoma (NSCLC) primarily treated by first generation tyrosine kinase inhibitors (TKI) and secondarily treated by third-generation TKI, such as osimertinib, if the EGFR-T790M resistance mutation is detected. Recently, significant prolonged progression free survival has been observed following first-line osimertinib, in EGFR-mutant NSLC. While mechanisms of molecular resistance to first-generation TKI have been well studied, little is known about resistance induced by primary third-generation TKI treatments. Read More

View Article and Full-Text PDF

Hypofractionated Intensity Modulated Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Prospective Clinical Trial (GASTO1011).

Pract Radiat Oncol 2021 Jun 19. Epub 2021 Jun 19.

Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou; State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou; Lung Cancer Institute of Sun Yat-sen University, Guangzhou.; Guangdong Association Study of Thoracic Oncology, Guangzhou. Electronic address:

Purpose: We aimed to explore the efficacy and toxicity of split-course hypofractionated radiotherapy with concurrent chemotherapy (HRT-CHT) in patients with locally advanced non-small cell lung cancer (LANSCLC) in this single-arm, phase II study.

Methods: LANSCLC patients were considered eligible if their forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC%) and carbon monoxide diffusing capacity (DLCO%) were ≥40% and ≥45%, respectively. HRT-CHT using the IMRT technique was administered with 51 Gy in 17 fractions as the first course followed by a break. Read More

View Article and Full-Text PDF

Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells.

Biochem Biophys Res Commun 2021 Jun 19;567:154-160. Epub 2021 Jun 19.

Department of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address:

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase and mutations in EGFR is a major driver force of lung cancer. EGFR tyrosine kinase inhibitors (TKIs) are group of promising agents to treat cancer patients with EGFR mutations. However, the application of TKIs is often hampered by the development of drug-resistance. Read More

View Article and Full-Text PDF

Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.

Pharmacol Res 2021 Jun 19:105734. Epub 2021 Jun 19.

Biological Resource Center, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China; Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, Nanchang 330006, China. Electronic address:

Objective: Cancer elicited inflammation is the main environmental cause leading to carcinogenesis and metastasis of non-small cell lung cancer (NSCLC). Roles of the inflammatory biomarker in predicting the clinical efficacy of tyrosine kinase inhibitor (TKI) and prognosis of naive patients with advanced NSCLC need to be determined, and the best inflammatory predicted biomarker remains unknown.

Methods: A total of 178 eligible advanced NSCLC patients (124 and 54 cases within discovery and validation cohorts, respectively) who received first-line EGFR-TKI between July of 2014 and October of 2020 were enrolled in the present study. Read More

View Article and Full-Text PDF

US Food and Drug Administration regulatory updates in neuro-oncology.

J Neurooncol 2021 Jun 22. Epub 2021 Jun 22.

Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

Objective: Contemporary management of patients with neuro-oncologic disease requires an understanding of approvals by the US Food and Drug Administration (FDA) related to nervous system tumors. To summarize FDA updates applicable to neuro-oncology practitioners, we sought to review oncology product approvals and Guidances that were pertinent to the field in the past year.

Methods: Oncology product approvals between January 1, 2020, and December 31, 2020, were reviewed for clinical trial outcomes involving tumors of the nervous system. Read More

View Article and Full-Text PDF

Immunotherapy era in the treatment of small cell lung cancer.

Med Oncol 2021 Jun 22;38(7):86. Epub 2021 Jun 22.

Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Yunus Emre Mah. Beyşehir Cad. No:281, Konya, Turkey.

Small cell lung cancer (SCLC) is differentiated from non-small cell lung cancers with its histological and morphological features, rapid response to chemotherapy, and recurrence in a short time after treatment is discontinued. Platinum plus etoposide chemotherapy combination has been used as a standard treatment, and no new drug has been found for more than 30 years in this disease. In research, the targeted pathways that may affect survival have not been identified yet. Read More

View Article and Full-Text PDF

First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.

Future Oncol 2021 Jun 22. Epub 2021 Jun 22.

Department of Pneumology & Thoracic Oncology, CH Annecy-Genevois, 74370, Metz-Tessy, France.

Pembrolizumab plus chemotherapy is currently used in the first-line treatment of advanced non-small-cell lung cancer without mutations or rearrangements, regardless of PD-L1 expression status. A study comparing chemotherapy plus pembrolizumab versus pembrolizumab alone has never been performed in patients with PD-L1 ≥50%. The aim of this trial is to perform such a comparison as first-line treatment in patients not eligible for locally advanced treatment who have expression of PD-L1 on ≥50% of tumor cells. Read More

View Article and Full-Text PDF

PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs.

Oncogene 2021 Jun 21. Epub 2021 Jun 21.

Center for Molecular Medicine, Research Center for Cancer Biology, and Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.

The tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) have been widely used for non-small cell lung cancer (NSCLC) patients, but the development of acquired resistance remains a therapeutic hurdle. The reduction of glucose uptake has been implicated in the anti-tumor activity of EGFR TKIs. In this study, the upregulation of the active sodium/glucose co-transporter 1 (SGLT1) was found to confer the development of acquired EGFR TKI resistance and was correlated with the poorer clinical outcome of the NSCLC patients who received EGFR TKI treatment. Read More

View Article and Full-Text PDF

Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion.

Sci Rep 2021 Jun 21;11(1):12965. Epub 2021 Jun 21.

Department of Medicine, Okayama Rosai Hospital, 1-10-25 Chikko Midorimachi, Minami-ku, Okayama, 702-8055, Japan.

Secretory leukocyte peptidase inhibitor (SLPI) is a biomarker present in the respiratory tract that protects against tissue destruction and aids in wound healing. We examined whether SLPI in pleural effusion can be used to distinguish benign asbestos pleural effusion (BAPE) from early-stage malignant pleural mesothelioma (MPM) and other diseases. We measured the levels of SLPI, hyaluronic acid (HA), soluble mesothelin-related peptides (SMRP), CCL2, galectin-3, and CYFRA21-1 in 51 patients with BAPE, 37 patients with early-stage MPM, 77 patients with pleural effusions due to non-small-cell lung cancer (LCa), and 74 patients with other pleural effusions. Read More

View Article and Full-Text PDF

Non-bacterial thrombotic endocarditis and coronary thrombectomy in a patient with metastatic small cell lung carcinoma.

BMJ Case Rep 2021 Jun 21;14(6). Epub 2021 Jun 21.

Division of Cardiology, Department of Internal Medicine, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA.

A 66-year-old Caucasian man was initially admitted with a metastatic small cell lung carcinoma, hyponatraemia and obstructive pneumonia. His transthoracic echocardiogram (TTE) was normal. Ten days after admission, he was diagnosed with a non-ST segment elevation myocardial infarction (MI). Read More

View Article and Full-Text PDF

Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in Non-Small Cell Lung Cancer.

BMB Rep 2021 Jun 22. Epub 2021 Jun 22.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Background: Owing to rapid advancements in NGS (next generation sequencing), genomic alteration is now considered an essential predictive biomarkers that impact the treatment decision in many cases of cancer. Among the various predictive biomarkers, tumor mutation burden (TMB) was identified by NGS and was considered to be useful in predicting a clinical response in cancer cases treated by immunotherapy. In this study, we directly compared the lab-developed-test (LDT) results by target sequencing panel, K-MASTER panel v3. Read More

View Article and Full-Text PDF

Future of lung cancer treatment.

Klin Onkol 2021 ;34(Supplementum 1):71-81

The evolution of lung cancer treatment is an example of new perspectives in clinical oncology. Genomically determined targeted therapy of non-small cell lung cancer (NSCLC) is developing very rapidly with the gradual identification of new target structures and the concomitant development of innovative drugs are a great promise for the future. The historical development of systemic treatment of NSCLC is a model example of the path to accurate (precise) treatment. Read More

View Article and Full-Text PDF
January 2021

Immunotherapy in the treatment of non-small cell lung cancer.

Klin Onkol 2021 ;34(Supplementum 1):54-64

Immunotherapy with check-point inhibitors has demonstrated remarkable therapeutic benefits in many oncological diagnoses, including non-small cell lung cancer (NSCLC). Based on the data from clinical trials, it has become an important part of the NSCLC treatment algorithm. Treatment with programmed cell death protein 1 / programmed death-ligand 1 inhibitors can be indicated in various ways: as monotherapy or combination of immunotherapy with cytotox--ic T-lymphocyte antigen 4 inhibitors or in combination with other treatment modalities - chemotherapy, antiangiogenic therapy and radiotherapy. Read More

View Article and Full-Text PDF
January 2021